INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Tak Paul Peter reported CADL

Director, Chief Executive Officer · Candel Therapeutics, Inc. · Candel Therapeutics, Inc. — Stock Option (Right to Buy)

Side
M
Value
—
Shares
125.0K
Price
—
Executed
Sep 10, 2026
Disclosed
Sep 11, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Sep 10 executedSep 11, 2026 disclosed

CADL · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
3/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+5 / 25

No reported dollar value · 8.3% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · CADL

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    OM
    Ostrovsky MariaGeneral Counsel
    CADLCandel Therapeutics, Inc.
    Grant or award
    		A—
    315.0K sh
    		Nov 3, 2026Nov 5, 2026
    traded Nov 3, 2026
    		+2dSEC FORM 4

    Evidence

    26
    TP
    Tak Paul PeterDirector, Chief Executive Officer
    CADLCandel Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$2.54M
    220.9K sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    10
    TP
    Tak Paul PeterDirector, Chief Executive Officer
    CADLCandel Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$194K
    125.0K sh
    		Sep 10, 2026Sep 11, 2026
    traded Sep 10, 2026
    		+1dSEC FORM 4

    Evidence

    15
    TP
    Tak Paul PeterDirector, Chief Executive Officer
    CADLCandel Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$621K
    59.4K sh
    		Sep 11, 2026Sep 11, 2026
    traded Sep 11, 2026
    		+0dSEC FORM 4

    Evidence

    8
    TS
    Tyagarajan SeshuChief Technology Officer
    CADLCandel Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$84K
    7,000 sh
    		Aug 17, 2026Aug 19, 2026
    traded Aug 17, 2026
    		+2dSEC FORM 4

    Evidence

    9
    LN
    Loggia NicolettaDirector
    CADLCandel Therapeutics, Inc.
    Grant or award
    		A$3,291
    381 sh
    		Jun 30, 2026Jul 1, 2026
    traded Jun 30, 2026
    		+1dSEC FORM 4

    Evidence

    17
    TS
    Tyagarajan SeshuChief Technology Officer
    CADLCandel Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$70K
    7,000 sh
    		Jun 29, 2026Jul 1, 2026
    traded Jun 29, 2026
    		+2dSEC FORM 4

    Evidence

    21
    BF
    Barone FrancescaChief Scientific Officer
    CADLCandel Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$236K
    23.4K sh
    		Jun 29, 2026Jul 1, 2026
    traded Jun 29, 2026
    		+2dSEC FORM 4

    Evidence

    9
    ND
    Nguyen DiemDirector
    CADLCandel Therapeutics, Inc.
    Grant or award
    		A—
    32.0K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    RM
    Radhakrishnan MahaDirector
    CADLCandel Therapeutics, Inc.
    Grant or award
    		A—
    32.0K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GR
    Gaeta ReneeDirector
    CADLCandel Therapeutics, Inc.
    Grant or award
    		A—
    32.0K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    LN
    Loggia NicolettaDirector
    CADLCandel Therapeutics, Inc.
    Grant or award
    		A—
    32.0K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MC
    Martell ChristopherDirector
    CADLCandel Therapeutics, Inc.
    Grant or award
    		A—
    32.0K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    NJ
    Nabel Gary J.Director
    CADLCandel Therapeutics, Inc.
    Grant or award
    		A—
    32.0K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001873905-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 10, 2026
    Published
    Sep 11, 2026
    Ingested by INSIDER
    Nov 5, 02:17 UTC
    Last re-read
    Nov 5, 02:17 UTC

    Extracted facts

    Filer
    Tak Paul Peter
    Role
    Director, Chief Executive Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Candel Therapeutics, Inc. — Stock Option (Right to Buy)
    Ticker
    CADL
    Shares
    125.0K
    Price per share
    $0
    Execution date (reported)
    Sep 10, 2026
    Owned after transaction
    1.64M shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    What this establishes

    Tak Paul Peter filed this Form 4 reporting a option exercise of CADL on Sep 10, 2026. It became public on Sep 11, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Chief Executive Officer
    Tak Paul Petercik:0001873905
    Issuer
    Candel Therapeutics, Inc.cik:0001841387

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.